VEGF-C gene therapy - Herantis Pharma

Drug Profile

VEGF-C gene therapy - Herantis Pharma

Alternative Names: Ad-VEGF-C - Herantis Pharma; Lymfactin

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor C expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lymphoedema

Most Recent Events

  • 16 Apr 2018 Herantis Pharma submits clinical trial application of a phase II trial for Lymphoedema before April 2018
  • 16 Apr 2018 Interim efficacy and adverse events data from a phase I trial in Lymphoedema released by Herantis Pharma
  • 02 Mar 2018 Herantis plans to submit an application to regulatory authorities for a phase II randomised, placebo-controlled clinical trial in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top